#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC – European Society for Medical Oncology (free) AND Nivolumab/Low-dose Ipilimumab: A Potential Chemotherapy-Sparing Option in Advanced NSCLC – Pharmacy Times (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

Related Commentary on Twitter

Chemo-naïve patients with adv #NSCLC with PD-L1 expression assigned to nivolumab + ipilimumab, nivolumab alone, or chemo. Patients receiving nivolumab + ipilimumab had better clin outcomes. See the CheckMate 227 trial. #ESMO19 https://t.co/jU9S62qZLa

— NEJM (@NEJM) September 28, 2019